C018 / Convalife - LARVOL DELTA

C018, a potent and selective CDK4&9 dual inhibitor (AACR 2026) - "Background: CDK4&6 inhibitors have been approved for the treatment of metastatic ER+&HER2- breast cancer, either as monotherapy or in combination with endocrine therapy. Our findings demonstrate that simultaneous inhibition of CDK4 and CDK9 may exert synergistic effects in overcoming palbociclib resistance. CDK4&9 dual inhibition represents a promising therapeutic strategy to overcome both endocrine therapy and CDK4&6 inhibitor resistance in ER+ breast cancer, warranting further clinical development as a novel approach for treating resistant breast cancer."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CCNE1 • CDK2 • CDK9 • ER • HER-2